60 Degrees Pharmaceuticals and Fathom Holdings Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
60 Degrees Pharmaceuticals (SXTP) and Fathom Holdings will be featured on the RedChip Small Stocks, Big Money show on Bloomberg TV, airing February 22, 2025, at 7 p.m. ET. The program reaches approximately 73 million U.S. homes.
In his interview, SXTP's CEO Geoffrey Dow discusses the company's focus on developing therapies for infectious diseases, including their FDA-approved antimalarial drug ARAKODA® (tafenoquine). The company plans to expand the drug's indications to treat other conditions like babesiosis.
Fathom Holdings' CEO Marco Fregenal highlights their innovative flat-fee commission model and proprietary intelliAgent platform, which integrates residential brokerage, mortgage, title, and SaaS offerings. The company's acquisition of My Home Group is expected to generate $110 million in 2025 revenue, with over 100 potential acquisition targets in pipeline.
60 Degrees Pharmaceuticals (SXTP) e Fathom Holdings saranno presentate nel programma RedChip Small Stocks, Big Money su Bloomberg TV, che andrà in onda il 22 febbraio 2025, alle 19:00 ET. Il programma raggiunge circa 73 milioni di case negli Stati Uniti.
Nell'intervista, il CEO di SXTP Geoffrey Dow discute dell'impegno dell'azienda nello sviluppo di terapie per malattie infettive, inclusa la loro medicina antimalarica approvata dalla FDA, ARAKODA® (tafenoquina). L'azienda prevede di ampliare le indicazioni del farmaco per trattare altre condizioni come la babesiosi.
Il CEO di Fathom Holdings Marco Fregenal mette in evidenza il loro innovativo modello di commissione a tariffa fissa e la piattaforma proprietaria intelliAgent, che integra brokeraggio residenziale, mutui, titoli e offerte SaaS. Si prevede che l'acquisizione di My Home Group genererà 110 milioni di dollari di fatturato nel 2025, con oltre 100 potenziali obiettivi di acquisizione in pipeline.
60 Degrees Pharmaceuticals (SXTP) y Fathom Holdings aparecerán en el programa RedChip Small Stocks, Big Money en Bloomberg TV, que se emitirá el 22 de febrero de 2025, a las 7 p.m. ET. El programa llega a aproximadamente 73 millones de hogares en EE. UU.
En su entrevista, el CEO de SXTP Geoffrey Dow habla sobre el enfoque de la empresa en el desarrollo de terapias para enfermedades infecciosas, incluyendo su medicamento antipalúdico aprobado por la FDA, ARAKODA® (tafenoquina). La empresa planea ampliar las indicaciones del medicamento para tratar otras condiciones como la babesiosis.
El CEO de Fathom Holdings Marco Fregenal destaca su innovador modelo de comisión de tarifa fija y la plataforma propietaria intelliAgent, que integra corretaje residencial, hipotecas, títulos y ofertas de SaaS. Se espera que la adquisición de My Home Group genere 110 millones de dólares en ingresos en 2025, con más de 100 objetivos de adquisición potenciales en la cartera.
60 Degrees Pharmaceuticals (SXTP)와 Fathom Holdings는 2025년 2월 22일 오후 7시 ET에 방송되는 Bloomberg TV의 RedChip Small Stocks, Big Money 쇼에 출연할 예정입니다. 이 프로그램은 약 7300만 가구에 도달합니다.
인터뷰에서 SXTP의 CEO Geoffrey Dow는 감염병 치료제를 개발하는 회사의 초점에 대해 이야기하며, FDA 승인을 받은 항말라리아 약물 ARAKODA® (tafenoquine)에 대해 설명합니다. 회사는 이 약물의 적응증을 확대하여 바베시아증과 같은 다른 질환을 치료할 계획입니다.
Fathom Holdings의 CEO Marco Fregenal은 혁신적인 고정 수수료 모델과 주거 중개, 모기지, 타이틀 및 SaaS 제공을 통합한 독점 플랫폼 intelliAgent를 강조합니다. My Home Group의 인수는 2025년 1억 1000만 달러의 수익을 창출할 것으로 예상되며, 100개 이상의 잠재적 인수 대상이 파이프라인에 있습니다.
60 Degrees Pharmaceuticals (SXTP) et Fathom Holdings seront présentés dans l'émission RedChip Small Stocks, Big Money sur Bloomberg TV, diffusée le 22 février 2025 à 19h00 ET. Le programme atteint environ 73 millions de foyers aux États-Unis.
Dans son interview, le PDG de SXTP Geoffrey Dow aborde l'engagement de l'entreprise à développer des thérapies pour les maladies infectieuses, y compris leur médicament antipaludique approuvé par la FDA, ARAKODA® (tafenoquine). L'entreprise prévoit d'élargir les indications du médicament pour traiter d'autres conditions telles que la babesiose.
Le PDG de Fathom Holdings Marco Fregenal met en avant leur modèle de commission à tarif fixe innovant et la plateforme propriétaire intelliAgent, qui intègre le courtage résidentiel, les prêts hypothécaires, les titres et les offres SaaS. L'acquisition de My Home Group devrait générer 110 millions de dollars de revenus en 2025, avec plus de 100 cibles d'acquisition potentielles dans le pipeline.
60 Degrees Pharmaceuticals (SXTP) und Fathom Holdings werden in der RedChip Small Stocks, Big Money Show auf Bloomberg TV vorgestellt, die am 22. Februar 2025 um 19:00 Uhr ET ausgestrahlt wird. Das Programm erreicht etwa 73 Millionen Haushalte in den USA.
In seinem Interview spricht der CEO von SXTP Geoffrey Dow über den Fokus des Unternehmens auf die Entwicklung von Therapien für Infektionskrankheiten, einschließlich ihres von der FDA zugelassenen Antimalariamittels ARAKODA® (Tafenoquin). Das Unternehmen plant, die Indikationen des Medikaments auf andere Erkrankungen wie Babesiose auszuweiten.
Der CEO von Fathom Holdings Marco Fregenal hebt ihr innovatives Flatrate-Provisionsmodell und die proprietäre intelliAgent-Plattform hervor, die Wohnimmobilienvermittlung, Hypotheken, Titel und SaaS-Angebote integriert. Die Übernahme von My Home Group wird voraussichtlich 110 Millionen Dollar Umsatz im Jahr 2025 generieren, mit über 100 potenziellen Übernahmezielen in der Pipeline.
- SXTP has an FDA-approved antimalarial drug ARAKODA® with potential expansion to other indications
- Fathom Holdings' acquisition of My Home Group projected to add $110 million in 2025 revenue
- Fathom has identified over 100 potential acquisition targets
- None.
ORLANDO, FL / ACCESS Newswire / February 21, 2025 / RedChip Companies will air interviews with 60 Degrees Pharmaceuticals, Inc. (Nasdaq:SXTP) and Fathom Holdings Inc. (Nasdaq:FTHM) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV this Saturday, February 22, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
Access the interviews in their entirety at:
In an exclusive interview, Geoffrey Dow, CEO and President of 60 Degrees Pharmaceuticals, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss the company's mission to develop and commercialize new therapies for infectious diseases. He highlights the FDA-approved antimalarial drug ARAKODA® (tafenoquine) and outlines plans to expand its indications to address other diseases, including babesiosis. Dow also emphasizes the company's commitment to addressing unmet medical needs and improving global health outcomes.
Marco Fregenal, CEO of Fathom Holdings, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss the company's disruptive approach to real estate services. He highlights Fathom's innovative flat-fee commission model, which allows agents to retain more of their earnings while driving industry-leading growth and retention rates. Fregenal also details how Fathom's proprietary intelliAgent platform integrates residential brokerage, mortgage, title, and SaaS offerings to create a scalable, cost-efficient business model that outperforms traditional brokerages. Additionally, he outlines the company's aggressive expansion strategy, including the successful acquisition of My Home Group, projected to add
SXTP and FTHM are clients of RedChip Companies. Please read our full disclosure at https://www.redchip.com/legal/disclosures.
About 60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases that affect the lives of millions of people. 60 Degrees Pharmaceuticals, Inc. achieved FDA approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention, in 2018. 60 Degrees Pharmaceuticals, Inc. also collaborates with prominent research organizations in the U.S., Australia, and Singapore. The 60 Degrees Pharmaceuticals, Inc. mission has been supported through in-kind funding from the U.S. Department of Defense and private institutional investors including Knight Therapeutics Inc., a Canadian-based pan-American specialty pharmaceutical company. 60 Degrees Pharmaceuticals, Inc. is headquartered in Washington D.C., with a majority-owned subsidiary in Australia. Learn more at www.60degreespharma.com. The statements contained herein may include prospects, statements of future expectations and other forward-looking statements that are based on management's current views and assumptions and involve known and unknown risks and uncertainties. Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements.
About Fathom Holdings Inc.
Fathom Holdings Inc. is a national, technology-driven real estate services platform integrating residential brokerage, mortgage, title, and SaaS offerings to brokerages and agents by leveraging its proprietary cloud-based software, intelliAgent. The Company's brands include Fathom Realty, Encompass Lending, intelliAgent, LiveBy, Real Results, and Verus Title. For more information, visit www.FathomInc.com.
About RedChip Companies
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 33 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.
To learn more about RedChip's products and services, please visit:
https://www.redchip.com/corporate/investor_relations
"Discovering Tomorrow's Blue Chips Today"™
Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/
Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies
Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/
Follow RedChip on Twitter: https://twitter.com/RedChip
Follow RedChip on YouTube: https://www.youtube.com/@redchip
Follow RedChip on Rumble: https://rumble.com/c/c-3068340
Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest
Contact:
Dave Gentry
RedChip Companies Inc.
1-407-644-4256
info@redchip.com
--END--
SOURCE: RedChip
View the original press release on ACCESS Newswire
FAQ
What is the potential revenue impact of My Home Group acquisition for FTHM in 2025?
What are the new indications being explored for SXTP's ARAKODA drug?
When will SXTP and FTHM interviews air on Bloomberg TV?
What is Fathom Holdings' main competitive advantage in the real estate market?
